Aldosterone receptor antagonists: current perspectives and therapies

References

• FunderJWMinireview: aldosterone and mineralocorticoid receptors: past, present, and futureEndocrinology2010151115098510220861235
   PubMed Web of Science ®Google Scholar
• ViengchareunSLe MenuetDMartinerieLThe mineralocorticoid receptor: insights into its molecular and (patho)physiological biologyNucl Recept Signal20075e01218174920
   PubMedGoogle Scholar
• FunderJWMinireview: aldosterone and the cardiovascular system: genomic and nongenomic effectsEndocrinology2006147125564556716946012
   PubMed Web of Science ®Google Scholar
• JuurlinkDNMamdaniMMLeeDSRates of hyperkalemia after publication of the Randomized Aldactone Evaluation StudyN Engl J Med2004351654355115295047
   PubMed Web of Science ®Google Scholar
• WithamMDGillespieNDStruthersADHyperkalemia after the publication of RALESN Engl J Med20043512324482450 author reply 2448–245015580679
   PubMedGoogle Scholar
• ZannadFGattis StoughWRossignolPMineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practiceEur Heart J201233222782279522942339
   PubMed Web of Science ®Google Scholar
• ShahKBRaoKSawyerRGottliebSSThe adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failureJ Am Coll Cardiol200546584584916139135
   PubMed Web of Science ®Google Scholar
• PittBBakrisGRuilopeLMDiCarloLMukherjeeREPHESUS InvestigatorsSerum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)Circulation2008118161643165018824643
   PubMed Web of Science ®Google Scholar
• JessupMAbrahamWTCaseyDE2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung TransplantationCirculation2009119141977201619324967
   PubMed Web of Science ®Google Scholar
• PisoniRAcelajadoMCCartmillFRLong-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney diseaseJ Hum Hypertens201226850250621677673
   PubMed Web of Science ®Google Scholar
• VardenyOWuDHDesaiAInfluence of Baseline and Worsening Renal Function on Efficacy of Spironolactone in Patients With Severe Heart Failure: Insights From RALES (Randomized Aldactone Evaluation Study)J Am Coll Cardiol201260202082208923083787
   PubMed Web of Science ®Google Scholar
• PittBAnkerSDBushinskyDAEvaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trialEur Heart J201132782082821208974
   PubMed Web of Science ®Google Scholar
• FunderJWCareyRMFardellaCCase detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guidelineJ Clin Endocrinol Metab20089393266328118552288
   PubMed Web of Science ®Google Scholar
• MossoLCarvajalCGonzalezAPrimary aldosteronism and hypertensive diseaseHypertension200342216116512796282
   PubMed Web of Science ®Google Scholar
• RossiGPDi BelloVGanzaroliCExcess aldosterone is associated with alterations of myocardial texture in primary aldosteronismHypertension2002401232712105133
   PubMed Web of Science ®Google Scholar
• MuiesanMLSalvettiMPainiAInappropriate left ventricular mass in patients with primary aldosteronismHypertension200852352953418645048
   PubMed Web of Science ®Google Scholar
• MilliezPGirerdXPlouinPFBlacherJSafarMEMouradJJEvidence for an increased rate of cardiovascular events in patients with primary aldosteronismJ Am Coll Cardiol1920054581243124815837256
   PubMedGoogle Scholar
• CatenaCColussiGNadaliniECardiovascular outcomes in patients with primary aldosteronism after treatmentArch Intern Med20081681808518195199
   PubMedGoogle Scholar
• Born-FrontsbergEReinckeMRumpLCCardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn’s RegistryJ Clin Endocrinol Metab20099441125113019190103
   PubMed Web of Science ®Google Scholar
• CatenaCColussiGLapennaRLong-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronismHypertension200750591191817893375
   PubMed Web of Science ®Google Scholar
• CatenaCColussiGDi FabioAMineralocorticoid antagonists treatment versus surgery in primary aldosteronismHorm Metab Res201042644044520119883
   PubMed Web of Science ®Google Scholar
• VasanRSEvansJCLarsonMGSerum aldosterone and the incidence of hypertension in nonhypertensive personsN Engl J Med20043511334115229305
   PubMed Web of Science ®Google Scholar
• RossiGPBerniniGCaliumiCA prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patientsJ Am Coll Cardiol200648112293230017161262
   PubMed Web of Science ®Google Scholar
• CalhounDANishizakaMKZamanMAThakkarRBWeissmannPHyperaldosteronism among black and white subjects with resistant hypertensionHypertension200240689289612468575
   PubMed Web of Science ®Google Scholar
• Pr att-UbunamaMNNishizakaMKBoedefeldRLCofieldSSHardingSMCalhounDAPlasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertensionChest2007131245345917296647
   PubMed Web of Science ®Google Scholar
• JeunemaitreXChatellierGKreft-JaisCEfficacy and tolerance of spironolactone in essential hypertensionAm J Cardiol198760108208253661395
   PubMed Web of Science ®Google Scholar
• WeinbergerMHRonikerBKrauseSLWeissRJEplerenone, a selective aldosterone blocker, in mild-to-moderate hypertensionAm J Hypertens200215870971612160194
   PubMed Web of Science ®Google Scholar
• FlackJMOparilSPrattJHEfficacy and tolerability of eplerenone and losartan in hypertensive black and white patientsJ Am Coll Cardiol20034171148115512679215
   PubMed Web of Science ®Google Scholar
• KrumHNollyHWorkmanDEfficacy of eplerenone added to renin-angiotensin blockade in hypertensive patientsHypertension200240211712312154100
   PubMed Web of Science ®Google Scholar
• SatoATakaneHSarutaTHigh serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patientsHypertens Res20012429910411325081
   PubMed Web of Science ®Google Scholar
• PittBReichekNWillenbrockREffects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy studyCirculation2003108151831183814517164
   PubMed Web of Science ®Google Scholar
• SavoiaCTouyzRMAmiriFSchiffrinELSelective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patientsHypertension200851243243918195160
   PubMed Web of Science ®Google Scholar
• LeenenFHRuzickaMFlorasJSCentral sympathetic inhibition by mineralocorticoid receptor but not angiotensin II type 1 receptor blockade: are prescribed doses too low?Hypertension201260227828022733463
   PubMed Web of Science ®Google Scholar
• KontakACWangZArbiqueDReversible sympathetic overactivity in hypertensive patients with primary aldosteronismJ Clin Endocrinol Metab201095104756476120660053
   PubMed Web of Science ®Google Scholar
• RahejaPPriceAWangZSpironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patientsHypertension201260231932522733474
   PubMed Web of Science ®Google Scholar
• CalhounDAJonesDTextorSResistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure ResearchCirculation200811725e510e52618574054
   PubMed Web of Science ®Google Scholar
• KumbhaniDJStegPGCannonCPResistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosisEur Heart J2012
   PubMed Web of Science ®Google Scholar
• GallayBJAhmadSXuLToivolaBDavidsonRCScreening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratioAm J Kidney Dis200137469970511273868
   PubMed Web of Science ®Google Scholar
• StrauchBZelinkaTHampfMBernhardtRWidimskyJJrPrevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe regionJ Hum Hypertens200317534935212756408
   PubMed Web of Science ®Google Scholar
• EideIKTorjesenPADrolsumABabovicALilledahlNPLow-renin status in therapy-resistant hypertension: a clue to efficient treatmentJ Hypertens200422112217222615480108
   PubMed Web of Science ®Google Scholar
• GaddamKKNishizakaMKPratt-UbunamaMNCharacterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansionArch Intern Med2008168111159116418541823
   PubMedGoogle Scholar
• GaddamKCorrosCPimentaERapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical studyHypertension20105551137114220351345
   PubMed Web of Science ®Google Scholar
• NishizakaMKZamanMACalhounDAEfficacy of low-dose spironolactone in subjects with resistant hypertensionAm J Hypertens20031611 Pt 192593014573330
   PubMed Web of Science ®Google Scholar
• ChapmanNDobsonJWilsonSEffect of spironolactone on blood pressure in subjects with resistant hypertensionHypertension200749483984517309946
   PubMed Web of Science ®Google Scholar
• de SouzaFMuxfeldtEFiszmanRSallesGEfficacy of spironolactone therapy in patients with true resistant hypertensionHypertension201055114715219858405
   PubMed Web of Science ®Google Scholar
• Alvarez-AlvarezBAbad-CardielMFernandez-CruzAMartell-ClarosNManagement of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone systemJ Hypertens201028112329233520651602
   PubMedGoogle Scholar
• NietoFJYoungTBLindBKAssociation of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health StudyJAMA2000283141829183610770144
   PubMed Web of Science ®Google Scholar
• LoganAGPerlikowskiSMMenteAHigh prevalence of unrecognized sleep apnoea in drug-resistant hypertensionJ Hypertens200119122271227711725173
   PubMed Web of Science ®Google Scholar
• GonzagaCCGaddamKKAhmedMISeverity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertensionJ Clin Sleep Med20106436336820726285
   PubMed Web of Science ®Google Scholar
• GaddamKPimentaEThomasSJSpironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary reportJ Hum Hypertens201024853253720016520
   PubMed Web of Science ®Google Scholar
• WeberKTAldosterone in congestive heart failureN Engl J Med2001345231689169711759649
   PubMed Web of Science ®Google Scholar
• PittB“Escape” of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapyCardiovasc Drugs Ther1995911451497786835
   PubMed Web of Science ®Google Scholar
• JordeUPVittorioTKatzSDColomboPCLatifFLe JemtelTHElevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failureCirculation200210691055105712196328
   PubMed Web of Science ®Google Scholar
• PittBZannadFRemmeWJThe effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study InvestigatorsN Engl J Med19993411070971710471456
   PubMed Web of Science ®Google Scholar
• ZannadFAllaFDoussetBPerezAPittBLimitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales InvestigatorsCirculation2000102222700270611094035
   PubMed Web of Science ®Google Scholar
• PittBRemmeWZannadFEplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarctionN Engl J Med2003348141309132112668699
   PubMed Web of Science ®Google Scholar
• HayashiMTsutamotoTWadaAImmediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarctionCirculation2003107202559256512732605
   PubMed Web of Science ®Google Scholar
• ZannadFMcMurrayJJKrumHEplerenone in patients with systolic heart failure and mild symptomsN Engl J Med1620113641112121073363
   PubMed Web of Science ®Google Scholar
• RogersJKMcMurrayJJPocockSJEplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizationsCirculation2012126192317232323042980
   PubMed Web of Science ®Google Scholar
• GrandiAMImperialeDSantilloRAldosterone antagonist improves diastolic function in essential hypertensionHypertension200240564765212411457
   PubMed Web of Science ®Google Scholar
• BoccanelliAMuredduGFCacciatoreGAnti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final resultsEur J Heart Fail2009111687619147459
   PubMed Web of Science ®Google Scholar
• BeyguiFVicautEEcollanPRationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trialAm Heart J2010160464264820934557
   PubMed Web of Science ®Google Scholar
• RossignolPMenardJFayRGustafssonFPittBZannadFEplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudyJ Am Coll Cardiol201158191958196622032706
   PubMed Web of Science ®Google Scholar
• AlbertNMYancyCWLiangLUse of aldosterone antagonists in heart failureJAMA2009302151658166519843900
   PubMed Web of Science ®Google Scholar
• SamuelJLDelcayreCHeart failure: aldosterone antagonists are underused by cliniciansNat Rev Cardiol20107312512720179719
   PubMed Web of Science ®Google Scholar
• RassiANCavenderMAFonarowGCTemporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarctionJ Am Coll Cardiol2012
   PubMedGoogle Scholar
• FonarowGCYancyCWHernandezAFPetersonEDSpertusJAHeidenreichPAPotential impact of optimal implementation of evidence-based heart failure therapies on mortalityAm Heart J2011161610241030e102321641346
   PubMed Web of Science ®Google Scholar
• FonarowGCAlbertNMCurtisABImproving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF)Circulation2010122658559620660805
   PubMed Web of Science ®Google Scholar
• MohammedSFOhtaniTKorinekJMineralocorticoid accelerates transition to heart failure with preserved ejection fraction via “nongenomic effects”Circulation2010122437037820625113
   PubMed Web of Science ®Google Scholar
• MottramPMHaluskaBLeanoRCowleyDStowasserMMarwickTHEffect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failureCirculation2004110555856515277317
   PubMed Web of Science ®Google Scholar
• MakGJLedwidgeMTWatsonCJNatural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenoneJ Am Coll Cardiol200954181674168219850207
   PubMed Web of Science ®Google Scholar
• EdwardsNCFerroCJKirkwoodHEffect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney diseaseAm J Cardiol2010106101505151121059444
   PubMed Web of Science ®Google Scholar
• DeswalARichardsonPBozkurtBMannDLResults of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF)J Card Fail201117863464221807324
   PubMed Web of Science ®Google Scholar
• EdelmannFWRSchmidtAGEffect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The Aldo-DHF randomized controlled trialJAMA2013309878179123443441
   PubMed Web of Science ®Google Scholar
• DesaiASLewisEFLiRRationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fractionAm Heart J20111626966972e91022137068
   PubMed Web of Science ®Google Scholar
• SechiLANovelloMLapennaRLong-term renal outcomes in patients with primary aldosteronismJAMA2006295222638264516772627
   PubMed Web of Science ®Google Scholar
• EpsteinMAldosterone blockade: an emerging strategy for abrogating progressive renal diseaseAm J Med20061191191291917071154
   PubMed Web of Science ®Google Scholar
• AbboudHHenrichWLClinical practice. Stage IV chronic kidney diseaseN Engl J Med20103621566520054047
   PubMed Web of Science ®Google Scholar
• WhiteWBDuprezDSt HillaireREffects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertensionHypertension20034151021102612682082
   PubMed Web of Science ®Google Scholar
• FurumatsuYNagasawaYTomidaKEffect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blockerHypertens Res2008311596718360019
   PubMed Web of Science ®Google Scholar
• NavaneethanSDNigwekarSUSehgalARStrippoliGFAldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysisClin J Am Soc Nephrol20094354255119261819
   PubMed Web of Science ®Google Scholar
• NielsenSEPerssonFFrandsenESpironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover studyDiabet Med2012298e184e19022268920
   PubMed Web of Science ®Google Scholar
• EdwardsNCSteedsRPChueCDStewartPMFerroCJTownendJNThe safety and tolerability of spironolactone in patients with mild to moderate chronic kidney diseaseBr J Clin Pharmacol201273344745421950312
   PubMed Web of Science ®Google Scholar
• ShavitLLifschitzMDEpsteinMAldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigmsKidney Int2012811095596822336987
   PubMed Web of Science ®Google Scholar
• KolkhofPBordenSAMolecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeuticsMol Cell Endocrinol242012350231031721771637
   PubMedGoogle Scholar
• BeermannBGroschinsky-GrindMClinical pharmacokinetics of diureticsClin Pharmacokinet1980532212456993083
   PubMed Web of Science ®Google Scholar
• HoPCBourneDWTriggsEJHeazlewoodVPharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactoneEur J Clin Pharmacol19842744414466519151
   PubMed Web of Science ®Google Scholar
• OverdiekHWHermensWAMerkusFWNew insights into the pharmacokinetics of spironolactoneClin Pharmacol Ther19853844694744042530
   PubMed Web of Science ®Google Scholar
• CookCSZhangLFischerJSAbsorption and disposition of a selective aldosterone receptor antagonist, eplerenone, in the dogPharm Res200017111426143111205738
   PubMed Web of Science ®Google Scholar
• CookCSBerryLMBibleRHHribarJDHajduELiuNWPharmacokinetics and metabolism of [14C]eplerenone after oral administration to humansDrug Metab Dispos200331111448145514570778
   PubMed Web of Science ®Google Scholar